Compare WHLR & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHLR | ADXN |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 10.3M |
| IPO Year | 2012 | N/A |
| Metric | WHLR | ADXN |
|---|---|---|
| Price | $1.81 | $7.99 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.4M | 7.1K |
| Earning Date | 11-06-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 61.36 | N/A |
| Revenue | ★ $101,834,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.03 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.69 | $6.51 |
| 52 Week High | $6,719.86 | $12.05 |
| Indicator | WHLR | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 48.25 |
| Support Level | $1.86 | $7.48 |
| Resistance Level | $6.85 | $8.90 |
| Average True Range (ATR) | 0.55 | 0.48 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 3.33 | 51.85 |
Wheeler Real Estate Investment Trust Inc is a self-managed commercial real estate investment company. It owns, leases, and operates income-producing retail properties with a primary focus on grocery-anchored centers. The company's properties include Alex City Marketplace in Alexander City, Alabama; Bryan Station in Lexington, Kentucky; Cardinal Plaza in Henderson, North Carolina; Clover Plaza in Clover, South Carolina; Winslow Plaza in Sicklerville, New Jersey and many more.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.